JP2009539870A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539870A5
JP2009539870A5 JP2009514512A JP2009514512A JP2009539870A5 JP 2009539870 A5 JP2009539870 A5 JP 2009539870A5 JP 2009514512 A JP2009514512 A JP 2009514512A JP 2009514512 A JP2009514512 A JP 2009514512A JP 2009539870 A5 JP2009539870 A5 JP 2009539870A5
Authority
JP
Japan
Prior art keywords
composition
dll4
antibody
effective amount
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009514512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/070516 external-priority patent/WO2007143689A2/en
Publication of JP2009539870A publication Critical patent/JP2009539870A/ja
Publication of JP2009539870A5 publication Critical patent/JP2009539870A5/ja
Pending legal-status Critical Current

Links

JP2009514512A 2006-06-06 2007-06-06 血管発生の調節ための組成物および方法 Pending JP2009539870A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81135706P 2006-06-06 2006-06-06
US86676706P 2006-11-21 2006-11-21
PCT/US2007/070516 WO2007143689A2 (en) 2006-06-06 2007-06-06 Compositions and methods for modulating vascular development

Publications (2)

Publication Number Publication Date
JP2009539870A JP2009539870A (ja) 2009-11-19
JP2009539870A5 true JP2009539870A5 (https=) 2011-06-30

Family

ID=38626647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514512A Pending JP2009539870A (ja) 2006-06-06 2007-06-06 血管発生の調節ための組成物および方法

Country Status (19)

Country Link
US (2) US20080014196A1 (https=)
EP (1) EP2029159A2 (https=)
JP (1) JP2009539870A (https=)
KR (1) KR20090016762A (https=)
AR (1) AR061245A1 (https=)
AU (1) AU2007256617A1 (https=)
BR (1) BRPI0710411A2 (https=)
CA (1) CA2654304A1 (https=)
CL (1) CL2007001624A1 (https=)
CR (1) CR10529A (https=)
EC (1) ECSP099032A (https=)
IL (1) IL194788A0 (https=)
MA (1) MA30536B1 (https=)
MX (1) MX2008015532A (https=)
NO (1) NO20090046L (https=)
RU (1) RU2008152435A (https=)
SG (1) SG172687A1 (https=)
TW (1) TW200817435A (https=)
WO (1) WO2007143689A2 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
DK1962895T3 (da) * 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
ME00591A (en) * 2006-08-07 2011-12-20 Use of dii4 antagonists in ishemic injury or vascular insufficiency
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
KR20100090683A (ko) 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
AU2009235467A1 (en) * 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
PE20100092A1 (es) * 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
NZ603698A (en) * 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
RU2581962C2 (ru) * 2008-09-19 2016-04-20 Медиммун Ллк Нацеленные средства связывания, направленные на dll4, и их применение
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011025964A2 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
CA2782299A1 (en) * 2009-12-01 2011-06-09 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR101330184B1 (ko) * 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
CA2862925C (en) 2012-02-10 2020-01-21 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
TR201908638T4 (tr) 2012-03-30 2019-07-22 Boehringer Ingelheim Int Ang2 bağlayıcı moleküller.
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
CN104661679A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
EP3826637A4 (en) * 2018-07-26 2022-05-04 The Regents of The University of California TREAT VESOOCCLUSION BY ACTIVATING NOTCH SIGNALING
US20220185875A1 (en) 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5545007A (en) * 1994-11-25 1996-08-13 United Technologies Corp. Engine blade clearance control system with piezoelectric actuator
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3957765B2 (ja) * 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP4171528B2 (ja) * 1997-05-14 2008-10-22 旭化成株式会社 新規な分化抑制剤
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) * 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
NZ536196A (en) * 2000-06-23 2006-12-22 Schering Ag Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE503829T1 (de) * 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EA200401325A1 (ru) * 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
US20040132140A1 (en) * 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4832719B2 (ja) * 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
US20040259150A1 (en) * 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
CA2481920A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
JPWO2005035778A1 (ja) * 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
EP1928486A2 (en) * 2005-09-01 2008-06-11 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
DK1962895T3 (da) * 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST

Similar Documents

Publication Publication Date Title
JP2009539870A5 (https=)
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
Moreno Garcia et al. Combining antiangiogenics to overcome resistance: rationale and clinical experience
JP2008528486A5 (https=)
Kleibeuker et al. Combining radiotherapy with sunitinib: lessons (to be) learned
Nechushtan et al. A phase 1/2 of a combination of cetuximab and taxane for “triple negative” breast cancer patients
JP2018531278A6 (ja) 癌のための併用療法
JP2018531278A (ja) 癌のための併用療法
Koukourakis et al. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
Pirker et al. Monoclonal antibodies against EGFR in non-small cell lung cancer
JP2018512402A5 (https=)
Bourdeanu et al. Targeted therapies in breast cancer: implications for advanced oncology practice
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
Novello et al. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study
Hoag et al. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review
JP2014510047A5 (https=)
Strumberg et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
George et al. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours
Sun et al. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
JP2021011484A (ja) 癌の治療のための抗ｖｅｇｆｒ−２抗体と抗ｐｄ−ｌ１抗体との組み合わせ
Abe et al. Safety assessment of intravenous administration of trastuzumab in 100ml saline for the treatment of HER2-positive breast cancer patients
Agostara et al. The management of cancer in the elderly: targeted therapies in oncology
Sharma et al. New and potential therapies for the treatment of Breast Cancer: An update for oncologists